View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRe:NewCell 과거 순이익 실적과거 기준 점검 0/6Re:NewCell 의 수입은 연평균 -52.6%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 3%의 비율로 증가했습니다. 매출은 연평균 95.5%의 비율로 증가해 왔습니다.핵심 정보-52.56%순이익 성장률-36.42%주당순이익(EPS) 성장률Chemicals 산업 성장률4.35%매출 성장률95.53%자기자본이익률-50.32%순이익률-195.60%다음 순이익 업데이트26 Apr 2024최근 과거 실적 업데이트공시 • Dec 23+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024Re:NewCell AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024Reported Earnings • Nov 08Third quarter 2023 earnings released: kr2.31 loss per share (vs kr2.99 loss in 3Q 2022)Third quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom.공시 • Nov 07Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024Reported Earnings • Aug 30Second quarter 2023 earnings released: kr2.82 loss per share (vs kr2.09 loss in 2Q 2022)Second quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom.공시 • Aug 30+ 2 more updatesRe:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024Re:NewCell AB (publ) announced that they will report Q4, 2023 results on Feb 13, 2024Reported Earnings • Apr 29Full year 2022 earnings released: kr8.99 loss per share (vs kr4.33 loss in FY 2021)Full year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.모든 업데이트 보기Recent updates공시 • Jun 05Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ).Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.Altor Equity Partners AB completed the acquisition of Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.공시 • Jan 10Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on SalesRe:NewCell AB announced that they are planning to start negotiations with the relevant trade unions regarding restructuring of the organization to improve efficiency while maintaining focus on sales. As part of the restructuring, the local authorities (Arbetsförmedlingen) will also be notified today. The planned restructuring will lead to a decrease in workforce of approximately 25%, just over 30 persons, and will also result in annual savings - reduction of personnel cost and other operating costs - of approximately 35 SEKm in total per annum when finalized.공시 • Dec 23+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024Re:NewCell AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024공시 • Dec 13Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024Re:NewCell AB (publ) announced Peter Schulz will join the company in the role of interim Chief Financial Officer (CFO) from 1 January 2024. He comes from a role as CFO at Pacific Basin Shipping (publ.) in Hong Kong, a position he has held for the past six years. Peter Schulz has extensive experience as CFO from both listed and private companies for the last 10 years. Prior to that Peter Schulz spent more than 15 years, and held senior positions, in investment banking in Stockholm, London and Hong Kong, among others with Royal Bank of Canada and ABN Amro. With his extensive and broad experience, he will contribute well to the management team and the company.Breakeven Date Change • Nov 22Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.Reported Earnings • Nov 08Third quarter 2023 earnings released: kr2.31 loss per share (vs kr2.99 loss in 3Q 2022)Third quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom.New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr107m net loss in 2 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (kr413.3m market cap, or US$37.8m).공시 • Nov 07Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024New Risk • Oct 18New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr408m Forecast net loss in 2 years: kr121m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr121m net loss in 2 years). Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr352.3m market cap, or US$31.9m).공시 • Oct 18Re:NewCell AB (publ) Announces CEO ChangesRe:NewCell AB (publ) announced that the Board has appointed Magnus Håkansson as the new acting CEO. Magnus has solid experience from leading roles in the retail and fashion sector and from leadership in a listed environment. He will start on October 16, 2023 and replaces Patrik Lundström, who has been the company's CEO since 2019. Magnus Håkansson was born in 1963, has a degree in economics from the Stockholm School of Economics and an MBA from MIT Sloan School of Management. He started his career as a management consultant at McKinsey and has since held several leading roles in global growth companies in the retail sector, as well as the pulp industry, including many years with experience from a listed environment. He most recently came from a role as CEO of MediaMarkt Sweden.Breakeven Date Change • Oct 16Forecast breakeven date pushed back to 2025The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr566.9m market cap, or US$51.4m).공시 • Oct 13Re:Newcell AB (Publ) Provides Earnings Guidance for the Third Quarter of 2023Re:NewCell AB (publ) provided earnings guidance for the third quarter of 2023. For the quarter, the company expected to report Net loss of approximately SEK 105 million.Recent Insider Transactions • Oct 10CEO & MD recently sold kr3.5m worth of stockOn the 6th of October, Patrik Lundstrom sold around 109k shares on-market at roughly kr31.70 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr16m. Patrik has been a net seller over the last 12 months, reducing personal holdings by kr19m.Reported Earnings • Aug 30Second quarter 2023 earnings released: kr2.82 loss per share (vs kr2.09 loss in 2Q 2022)Second quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom.공시 • Aug 30+ 2 more updatesRe:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024Re:NewCell AB (publ) announced that they will report Q4, 2023 results on Feb 13, 2024Breakeven Date Change • Aug 24Forecast breakeven date pushed back to 2025The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr233.9m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.Recent Insider Transactions • Aug 01CEO & MD recently sold kr16m worth of stockOn the 27th of July, Patrik Lundstrom sold around 224k shares on-market at roughly kr71.36 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.공시 • Jul 17Re:NewCell AB (publ) Announces Toby Lawton to Leave His Position as CFORe:NewCell AB (publ) Toby Lawton, CFO at Renewcell AB (publ), has announced that he will leave his position for a similar position in another company. Toby will continue to work as CFO until a successor has been appointed or at the latest until the end of the year.공시 • Jul 01Re:Newcell AB (Publ) Provides Production from Renewcell 1 Guidance in June 2023Re:NewCell AB (publ) provided production from Renewcell 1 guidance in June 2023. Production from Renewcell 1 is expected to reach 2,200-2,400 metric tons in June 2023, of which 2,100-2,300 metric tons are expected to be of prime quality and 2,200-2,400 metric tons are expected to be delivered to customers. The production in the month has been impacted by maintenance stops to upgrade and install new equipment in the shredding area.Reported Earnings • Apr 29Full year 2022 earnings released: kr8.99 loss per share (vs kr4.33 loss in FY 2021)Full year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.공시 • Feb 16+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2023 Results on Nov 07, 2023Re:NewCell AB (publ) announced that they will report Q3, 2023 results on Nov 07, 2023Reported Earnings • Feb 16Full year 2022 earnings released: kr8.99 loss per share (vs kr4.33 loss in FY 2021)Full year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom.Breakeven Date Change • Feb 08Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr51.6m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 22% per year to 2023. The company is expected to make a profit of kr118.9m in 2024. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Breakeven Date Change • Oct 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr122.1m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule.Reported Earnings • Oct 28Third quarter 2022 earnings released: kr2.99 loss per share (vs kr0.80 loss in 3Q 2021)Third quarter 2022 results: kr2.99 loss per share (further deteriorated from kr0.80 loss in 3Q 2021). Net loss: kr101.5m (loss widened 314% from 3Q 2021). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 8.6% decline forecast for the Chemicals industry in the United Kingdom.공시 • Oct 28+ 1 more updateRe:NewCell AB (publ) to Report Q2, 2023 Results on Aug 18, 2023Re:NewCell AB (publ) announced that they will report Q2, 2023 results on Aug 18, 2023Reported Earnings • Aug 26Second quarter 2022 earnings released: kr2.09 loss per share (vs kr0.76 loss in 2Q 2021)Second quarter 2022 results: kr2.09 loss per share (down from kr0.76 loss in 2Q 2021). Net loss: kr68.4m (loss widened 192% from 2Q 2021). Over the next year, revenue is forecast to grow 3,859% compared to a 21% decline forecast for the Chemicals industry in the United Kingdom.Board Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • May 24Chief Financial Officer recently bought kr116k worth of stockOn the 18th of May, Hugo Petit bought around 1k shares on-market at roughly kr116 per share. This was the largest purchase by an insider in the last 3 months. Hugo has been a buyer over the last 12 months, purchasing a net total of kr479k worth in shares.Reported Earnings • May 05First quarter 2022 earnings released: kr1.75 loss per share (vs kr0.63 loss in 1Q 2021)First quarter 2022 results: kr1.75 loss per share (down from kr0.63 loss in 1Q 2021). Net loss: kr54.0m (loss widened 181% from 1Q 2021). Over the next year, revenue is forecast to grow 4,106% compared to a 17% decline forecast for the industry in the United Kingdom.공시 • May 05Re:NewCell AB (publ) to Report Q1, 2023 Results on May 03, 2023Re:NewCell AB (publ) announced that they will report Q1, 2023 results on May 03, 2023Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Breakeven Date Change • Mar 09Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Recent Insider Transactions • Mar 03Chief Growth Officer recently sold kr65k worth of stockOn the 28th of February, Harald Cavalli-Bjorkman sold around 500 shares on-market at roughly kr129 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr1.6m more than they sold in the last 12 months.Breakeven Date Change • Feb 19Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.공시 • Feb 17Re:NewCell AB (publ) to Report Q4, 2022 Results on Feb 15, 2023Re:NewCell AB (publ) announced that they will report Q4, 2022 results on Feb 15, 2023Reported Earnings • Feb 17Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr4.33 loss per share (down from kr3.34 loss in FY 2020). Net loss: kr133.4m (loss widened 94% from FY 2020). Revenue exceeded analyst estimates by 10%. Over the next year, revenue is forecast to grow 1,979% compared to a 3.7% decline forecast for the industry in the United Kingdom.Breakeven Date Change • Jan 26Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Recent Insider Transactions • Jan 14Chief Financial Officer recently bought kr80k worth of stockOn the 12th of January, Hugo Petit bought around 425 shares on-market at roughly kr187 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. Hugo has been a buyer over the last 12 months, purchasing a net total of kr319k worth in shares.Breakeven Date Change • Jan 07Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Recent Insider Transactions • Dec 18Chief Executive Officer recently bought kr100k worth of stockOn the 14th of December, Patrik Lundstrom bought around 450 shares on-market at roughly kr221 per share. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of kr613k worth in shares.Reported Earnings • Nov 07Third quarter 2021 earnings released: kr0.80 loss per share (vs kr0.81 loss in 3Q 2020)Third quarter 2021 results: Net loss: kr24.5m (loss widened 55% from 3Q 2020).Recent Insider Transactions • Jun 24Plant Manager Ortviken recently bought kr108k worth of stockOn the 21st of June, Henrik Dahlbom bought around 700 shares on-market at roughly kr155 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr513k. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jun 13Chief Executive Officer recently bought kr513k worth of stockOn the 11th of June, Patrik Lundstrom bought around 3k shares on-market at roughly kr183 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.Recent Insider Transactions • May 24Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.Executive Departure • May 22Director has left the companyOn the 19th of May, Erik Karlsson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Erik's name. A total of 3 executives have left over the last 12 months.Executive Departure • May 22Director has left the companyOn the 19th of May, Henrik Norlin's tenure in the role of Director ended. We don't have any record of a personal shareholding under Henrik's name. A total of 3 executives have left over the last 12 months.Recent Insider Transactions • May 21Interim Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.Reported Earnings • May 07First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr19.3m (loss widened 58% from 1Q 2020).매출 및 비용 세부 내역Re:NewCell가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이LSE:0A5U 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비30 Sep 23205-401199030 Jun 23124-408203031 Mar 2341-371201031 Dec 2214-300185030 Sep 229-290190030 Jun 226-213159031 Mar 224-168130031 Dec 214-133103030 Sep 212-8877030 Jun 211-8068031 Mar 212-7261031 Dec 201-6957030 Sep 202-6046031 Dec 191-3832031 Dec 180-18220양질의 수익: 0A5U 은(는) 현재 수익성이 없습니다.이익 마진 증가: 0A5U는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 0A5U은 수익성이 없으며 지난 5년 동안 손실이 연평균 52.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 0A5U의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 0A5U은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(-59.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 0A5U는 현재 수익성이 없으므로 자본 수익률이 음수(-50.32%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/29 17:39종가2024/02/29 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Re:NewCell AB (publ)는 2명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Daniel OvinNordea MarketsJohan SpetzPareto Securities
공시 • Dec 23+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024Re:NewCell AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024
Reported Earnings • Nov 08Third quarter 2023 earnings released: kr2.31 loss per share (vs kr2.99 loss in 3Q 2022)Third quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Nov 07Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024
Reported Earnings • Aug 30Second quarter 2023 earnings released: kr2.82 loss per share (vs kr2.09 loss in 2Q 2022)Second quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Aug 30+ 2 more updatesRe:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024Re:NewCell AB (publ) announced that they will report Q4, 2023 results on Feb 13, 2024
Reported Earnings • Apr 29Full year 2022 earnings released: kr8.99 loss per share (vs kr4.33 loss in FY 2021)Full year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.
공시 • Jun 05Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ).Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.Altor Equity Partners AB completed the acquisition of Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.
공시 • Jan 10Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on SalesRe:NewCell AB announced that they are planning to start negotiations with the relevant trade unions regarding restructuring of the organization to improve efficiency while maintaining focus on sales. As part of the restructuring, the local authorities (Arbetsförmedlingen) will also be notified today. The planned restructuring will lead to a decrease in workforce of approximately 25%, just over 30 persons, and will also result in annual savings - reduction of personnel cost and other operating costs - of approximately 35 SEKm in total per annum when finalized.
공시 • Dec 23+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024Re:NewCell AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024
공시 • Dec 13Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024Re:NewCell AB (publ) announced Peter Schulz will join the company in the role of interim Chief Financial Officer (CFO) from 1 January 2024. He comes from a role as CFO at Pacific Basin Shipping (publ.) in Hong Kong, a position he has held for the past six years. Peter Schulz has extensive experience as CFO from both listed and private companies for the last 10 years. Prior to that Peter Schulz spent more than 15 years, and held senior positions, in investment banking in Stockholm, London and Hong Kong, among others with Royal Bank of Canada and ABN Amro. With his extensive and broad experience, he will contribute well to the management team and the company.
Breakeven Date Change • Nov 22Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
Reported Earnings • Nov 08Third quarter 2023 earnings released: kr2.31 loss per share (vs kr2.99 loss in 3Q 2022)Third quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom.
New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr107m net loss in 2 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (kr413.3m market cap, or US$37.8m).
공시 • Nov 07Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024
New Risk • Oct 18New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr408m Forecast net loss in 2 years: kr121m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr121m net loss in 2 years). Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr352.3m market cap, or US$31.9m).
공시 • Oct 18Re:NewCell AB (publ) Announces CEO ChangesRe:NewCell AB (publ) announced that the Board has appointed Magnus Håkansson as the new acting CEO. Magnus has solid experience from leading roles in the retail and fashion sector and from leadership in a listed environment. He will start on October 16, 2023 and replaces Patrik Lundström, who has been the company's CEO since 2019. Magnus Håkansson was born in 1963, has a degree in economics from the Stockholm School of Economics and an MBA from MIT Sloan School of Management. He started his career as a management consultant at McKinsey and has since held several leading roles in global growth companies in the retail sector, as well as the pulp industry, including many years with experience from a listed environment. He most recently came from a role as CEO of MediaMarkt Sweden.
Breakeven Date Change • Oct 16Forecast breakeven date pushed back to 2025The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr566.9m market cap, or US$51.4m).
공시 • Oct 13Re:Newcell AB (Publ) Provides Earnings Guidance for the Third Quarter of 2023Re:NewCell AB (publ) provided earnings guidance for the third quarter of 2023. For the quarter, the company expected to report Net loss of approximately SEK 105 million.
Recent Insider Transactions • Oct 10CEO & MD recently sold kr3.5m worth of stockOn the 6th of October, Patrik Lundstrom sold around 109k shares on-market at roughly kr31.70 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr16m. Patrik has been a net seller over the last 12 months, reducing personal holdings by kr19m.
Reported Earnings • Aug 30Second quarter 2023 earnings released: kr2.82 loss per share (vs kr2.09 loss in 2Q 2022)Second quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Aug 30+ 2 more updatesRe:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024Re:NewCell AB (publ) announced that they will report Q4, 2023 results on Feb 13, 2024
Breakeven Date Change • Aug 24Forecast breakeven date pushed back to 2025The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr233.9m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
Recent Insider Transactions • Aug 01CEO & MD recently sold kr16m worth of stockOn the 27th of July, Patrik Lundstrom sold around 224k shares on-market at roughly kr71.36 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.
공시 • Jul 17Re:NewCell AB (publ) Announces Toby Lawton to Leave His Position as CFORe:NewCell AB (publ) Toby Lawton, CFO at Renewcell AB (publ), has announced that he will leave his position for a similar position in another company. Toby will continue to work as CFO until a successor has been appointed or at the latest until the end of the year.
공시 • Jul 01Re:Newcell AB (Publ) Provides Production from Renewcell 1 Guidance in June 2023Re:NewCell AB (publ) provided production from Renewcell 1 guidance in June 2023. Production from Renewcell 1 is expected to reach 2,200-2,400 metric tons in June 2023, of which 2,100-2,300 metric tons are expected to be of prime quality and 2,200-2,400 metric tons are expected to be delivered to customers. The production in the month has been impacted by maintenance stops to upgrade and install new equipment in the shredding area.
Reported Earnings • Apr 29Full year 2022 earnings released: kr8.99 loss per share (vs kr4.33 loss in FY 2021)Full year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.
공시 • Feb 16+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2023 Results on Nov 07, 2023Re:NewCell AB (publ) announced that they will report Q3, 2023 results on Nov 07, 2023
Reported Earnings • Feb 16Full year 2022 earnings released: kr8.99 loss per share (vs kr4.33 loss in FY 2021)Full year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom.
Breakeven Date Change • Feb 08Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr51.6m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 22% per year to 2023. The company is expected to make a profit of kr118.9m in 2024. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Breakeven Date Change • Oct 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr122.1m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
Reported Earnings • Oct 28Third quarter 2022 earnings released: kr2.99 loss per share (vs kr0.80 loss in 3Q 2021)Third quarter 2022 results: kr2.99 loss per share (further deteriorated from kr0.80 loss in 3Q 2021). Net loss: kr101.5m (loss widened 314% from 3Q 2021). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 8.6% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Oct 28+ 1 more updateRe:NewCell AB (publ) to Report Q2, 2023 Results on Aug 18, 2023Re:NewCell AB (publ) announced that they will report Q2, 2023 results on Aug 18, 2023
Reported Earnings • Aug 26Second quarter 2022 earnings released: kr2.09 loss per share (vs kr0.76 loss in 2Q 2021)Second quarter 2022 results: kr2.09 loss per share (down from kr0.76 loss in 2Q 2021). Net loss: kr68.4m (loss widened 192% from 2Q 2021). Over the next year, revenue is forecast to grow 3,859% compared to a 21% decline forecast for the Chemicals industry in the United Kingdom.
Board Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • May 24Chief Financial Officer recently bought kr116k worth of stockOn the 18th of May, Hugo Petit bought around 1k shares on-market at roughly kr116 per share. This was the largest purchase by an insider in the last 3 months. Hugo has been a buyer over the last 12 months, purchasing a net total of kr479k worth in shares.
Reported Earnings • May 05First quarter 2022 earnings released: kr1.75 loss per share (vs kr0.63 loss in 1Q 2021)First quarter 2022 results: kr1.75 loss per share (down from kr0.63 loss in 1Q 2021). Net loss: kr54.0m (loss widened 181% from 1Q 2021). Over the next year, revenue is forecast to grow 4,106% compared to a 17% decline forecast for the industry in the United Kingdom.
공시 • May 05Re:NewCell AB (publ) to Report Q1, 2023 Results on May 03, 2023Re:NewCell AB (publ) announced that they will report Q1, 2023 results on May 03, 2023
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Breakeven Date Change • Mar 09Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Recent Insider Transactions • Mar 03Chief Growth Officer recently sold kr65k worth of stockOn the 28th of February, Harald Cavalli-Bjorkman sold around 500 shares on-market at roughly kr129 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr1.6m more than they sold in the last 12 months.
Breakeven Date Change • Feb 19Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
공시 • Feb 17Re:NewCell AB (publ) to Report Q4, 2022 Results on Feb 15, 2023Re:NewCell AB (publ) announced that they will report Q4, 2022 results on Feb 15, 2023
Reported Earnings • Feb 17Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr4.33 loss per share (down from kr3.34 loss in FY 2020). Net loss: kr133.4m (loss widened 94% from FY 2020). Revenue exceeded analyst estimates by 10%. Over the next year, revenue is forecast to grow 1,979% compared to a 3.7% decline forecast for the industry in the United Kingdom.
Breakeven Date Change • Jan 26Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Recent Insider Transactions • Jan 14Chief Financial Officer recently bought kr80k worth of stockOn the 12th of January, Hugo Petit bought around 425 shares on-market at roughly kr187 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. Hugo has been a buyer over the last 12 months, purchasing a net total of kr319k worth in shares.
Breakeven Date Change • Jan 07Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Recent Insider Transactions • Dec 18Chief Executive Officer recently bought kr100k worth of stockOn the 14th of December, Patrik Lundstrom bought around 450 shares on-market at roughly kr221 per share. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of kr613k worth in shares.
Reported Earnings • Nov 07Third quarter 2021 earnings released: kr0.80 loss per share (vs kr0.81 loss in 3Q 2020)Third quarter 2021 results: Net loss: kr24.5m (loss widened 55% from 3Q 2020).
Recent Insider Transactions • Jun 24Plant Manager Ortviken recently bought kr108k worth of stockOn the 21st of June, Henrik Dahlbom bought around 700 shares on-market at roughly kr155 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr513k. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jun 13Chief Executive Officer recently bought kr513k worth of stockOn the 11th of June, Patrik Lundstrom bought around 3k shares on-market at roughly kr183 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.
Recent Insider Transactions • May 24Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.
Executive Departure • May 22Director has left the companyOn the 19th of May, Erik Karlsson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Erik's name. A total of 3 executives have left over the last 12 months.
Executive Departure • May 22Director has left the companyOn the 19th of May, Henrik Norlin's tenure in the role of Director ended. We don't have any record of a personal shareholding under Henrik's name. A total of 3 executives have left over the last 12 months.
Recent Insider Transactions • May 21Interim Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.
Reported Earnings • May 07First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr19.3m (loss widened 58% from 1Q 2020).